COLORADO RESEARCH PARTNERS, LLC

Biotech · Private

Small-molecule therapeutic that blocks fructokinase C (KHK-C) enzyme to inhibit fructose metabolism

Grants
$1.4M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Scientific Merit and Feasibility of Fructokinase Inhibiton for Obesity$183,693
Federal grantDepartment of Health and Human Services · Phase II · Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity$289,373
Federal grantDepartment of Health and Human Services · Phase II · Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity$769,627
Federal grantDepartment of Health and Human Services · Phase II · Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity$206,585
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2396NeuvaRx, LLC——
2397Antiva Biosciences—$81M
2398Fate Therapeutics—$236M
2399COLORADO RESEARCH PARTNERS, LLC——
2400Halda Therapeutics—$198M
2401MCM6 THERAPEUTICS, INC.——
2402IZON Technologies, LLC—$1.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 1

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.